What Most People Get Wrong About Vaccine Court
Vaccine Court decides compensation, not whether a vaccine is safe or effective
The Vaccine Injury Compensation Program (VICP), often called “vaccine court,” is one of the most misunderstood federal programs in the United States.
It is frequently described as:
A secretive tribunal protecting pharmaceutical companies
Proof that vaccines are unsafe
A system where manufacturers have “total immunity”
Or a court that decides whether vaccines are safe
None of those characterizations accurately describe how the program works.
Vaccine court is a no-fault compensation system, not a scientific regulatory body. Understanding what it was designed to do — and what it was not designed to do — is essential to having an honest conversation about vaccine injury law and vaccine safety.
What Vaccine Court Was Designed to Do — and What It Was Not
A fundamental misunderstanding about vaccine court is the belief that its purpose is to determine whether vaccines are “safe” or “unsafe.”
That is not its function.
The Vaccine Injury Compensation Program was not created to conduct population-level scientific determinations about vaccine safety. It was created to compensate individuals efficiently and fairly when credible evidence supports that a vaccine may have caused a rare injury in a specific person.
Certain injuries are placed on the Vaccine Injury Table when medical and scientific evidence provides sufficient support for a potential causal association in rare instances. That is a policy decision — grounded in science — to allow those cases to be compensated more expeditiously without requiring individualized proof of biological mechanism in every case.
The inclusion of an injury on the Table does not mean the vaccine is unsafe. It does not mean the injury is common. It reflects a legislative judgment that, where credible scientific evidence supports a possible causal link in rare cases, affected individuals should not be required to relitigate complex scientific questions repeatedly.
For injuries not listed on the Table, petitioners may still prevail under the causation-in-fact standard. When a Special Master rules that a vaccine caused an injury in a specific individual, that ruling does not constitute a broad scientific declaration that the vaccine increases population-wide risk. It is a case-specific determination based on the evidence presented in that record.
Court decisions in vaccine cases are not safety verdicts. They are individualized compensation determinations.
A ruling that compensation is appropriate does not prove a vaccine is unsafe. A ruling denying compensation does not prove a vaccine is safe. It simply reflects whether the petitioner met the legal burden in that case.
Vaccine court is a compensation system, not a scientific regulatory agency. Confusing its purpose distorts both public understanding of vaccine safety and the role of the compensation program itself.
Myth #1: “Vaccine Court Is a Kangaroo Court”
Vaccine court operates within the U.S. Court of Federal Claims. Special Masters are judicial officers. Decisions are published. Petitioners do not need to prove negligence or product defect.
The system was designed to remove traditional tort barriers and provide a structured path to compensation for rare injuries. It is not a secret tribunal and it is not designed to suppress claims.
Myth #2: “If the Government Pays Claims, Vaccines Must Be Unsafe”
The VICP is a no-fault compensation program. Compensation does not require proof of defect or wrongdoing.
Vaccines are administered to millions of healthy individuals. Even extremely rare adverse events will appear at scale. Paying claims acknowledges that rare injuries can occur. It does not establish that vaccines are broadly unsafe.
Compensation is not a safety verdict.
Myth #3: “Manufacturers Have Total Immunity”
Vaccine manufacturers do not have absolute immunity. The Vaccine Act requires most claims to proceed through the VICP before traditional civil litigation.
This structure replaced unpredictable jury verdicts with a stable compensation framework. Manufacturers fund the compensation system through a per-dose excise tax. In exchange, most civil suits are preempted.
Liability protection was paired with compensation — not granted in isolation.
Myth #4: “You Must Prove Scientific Certainty to Win”
Vaccine court does not require scientific certainty.
Petitioners must show by a preponderance of the evidence that:
The vaccine can cause the injury, and
The vaccine did cause the injury in their case.
Biological plausibility and case-specific evidence matter. Epidemiological certainty is not required.
Myth #5: “If Vaccines Are Safe, Why Do Manufacturers Need Liability Protection?”
This is one of the most common and intuitive questions.
If vaccines are safe, why would manufacturers need immunity from civil lawsuits?
The answer lies in the nature of vaccination itself.
Vaccines are administered to millions of healthy individuals, including infants and children. Even when adverse events are extremely rare, administering a product at that scale means that a small number of serious injuries will inevitably occur. That statistical reality does not mean the product is defective. It means no medical intervention carries zero risk.
In the early 1980s, unpredictable jury verdicts and rising litigation costs threatened the stability of the U.S. vaccine supply. Manufacturers began leaving the market. Insurance premiums surged. Public health officials warned that essential childhood vaccines could become unavailable.
Congress responded in 1986 with the National Childhood Vaccine Injury Act. The Act created a grand bargain:
Manufacturers would contribute to a compensation trust fund through a per-dose excise tax.
Individuals injured by vaccines would receive compensation through a no-fault system.
In exchange, manufacturers would be protected from most traditional civil litigation.
This structure was not an admission that vaccines were unsafe. It was recognition that civil tort law is poorly suited to adjudicate rare, biologically complex injuries in mass public health programs.
In civil court, plaintiffs must prove product defect (design, manufacturing, or failure to warn) and survive strict evidentiary standards such as Daubert challenges. Historically, the probability of success in civil vaccine litigation has been low. Courts often exclude expert testimony when large epidemiological studies are unavailable.
The Vaccine Injury Compensation Program lowers the burden appropriately. Petitioners need not prove negligence or defect. They must show by a preponderance of the evidence that a vaccine can cause the injury and that it did so in their case.
Liability protection and compensation are not contradictions. They are two parts of a deliberate policy structure designed to preserve vaccine supply while ensuring fair compensation for rare injuries.
If manufacturers are required to fund a compensation program specifically for vaccine injuries, subjecting them to full and unpredictable civil litigation on top of that structure would undermine the stability the Act was designed to create.
The existence of liability protection does not imply vaccines are unsafe. It reflects the unique role vaccines play in public health and the need for a predictable, balanced system.
Final Perspective
Viruses do not play politics.
Vaccines remain one of the most effective public health tools ever developed. Rare injuries can occur — and when they do, they deserve fair compensation.
The Vaccine Injury Compensation Program was created to handle that reality. It was not designed to determine whether vaccines are safe or unsafe. It was designed to compensate rare injuries efficiently and consistently while preserving vaccine supply.
Clear understanding — not rhetoric — is what protects both public health and public trust.